Sequence variation does not confound the measurement of plasma PfHRP2 concentration in African children presenting with severe malaria by Ramutton, Thiranut et al.
Ramutton et al. Malaria Journal 2012, 11:276
http://www.malariajournal.com/content/11/1/276RESEARCH Open AccessSequence variation does not confound the
measurement of plasma PfHRP2 concentration in
African children presenting with severe malaria
Thiranut Ramutton1, Ilse CE Hendriksen2,3, Juliet Mwanga-Amumpaire4, George Mtove5, Rasaq Olaosebikan6,
Antoinette K Tshefu7, Marie A Onyamboko7, Corine Karema8, Kathryn Maitland9, Ermelinda Gomes10,
Samwel Gesase11, Hugh Reyburn12, Kamolrat Silamut2, Kesinee Chotivanich2, Kamoltip Promnares13,14,
Caterina I Fanello2,3, Lorenz von Seidlein15, Nicholas PJ Day2,3, Nicholas J White2,3, Arjen M Dondorp2,3,
Mallika Imwong2,16* and Charles J Woodrow2,3*Abstract
Background: Plasmodium falciparum histidine-rich protein PFHRP2 measurement is used widely for diagnosis, and
more recently for severity assessment in falciparum malaria. The Pfhrp2 gene is highly polymorphic, with deletion of
the entire gene reported in both laboratory and field isolates. These issues potentially confound the interpretation
of PFHRP2 measurements.
Methods: Studies designed to detect deletion of Pfhrp2 and its paralog Pfhrp3 were undertaken with samples from
patients in seven countries contributing to the largest hospital-based severe malaria trial (AQUAMAT). The
quantitative relationship between sequence polymorphism and PFHRP2 plasma concentration was examined in
samples from selected sites in Mozambique and Tanzania.
Results: There was no evidence for deletion of either Pfhrp2 or Pfhrp3 in the 77 samples with lowest PFHRP2
plasma concentrations across the seven countries. Pfhrp2 sequence diversity was very high with no haplotypes
shared among 66 samples sequenced. There was no correlation between Pfhrp2 sequence length or repeat type
and PFHRP2 plasma concentration.
Conclusions: These findings indicate that sequence polymorphism is not a significant cause of variation in PFHRP2
concentration in plasma samples from African children. This justifies the further development of plasma PFHRP2
concentration as a method for assessing African children who may have severe falciparum malaria. The data also
add to the existing evidence base supporting the use of rapid diagnostic tests based on PFHRP2 detection.
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The Plasmodium falciparum histidine-rich proteins
PFHRP2 and PFHRP3 [1] are soluble proteins contain-
ing highly antigenic tandem repeat sequences [2] and
are produced in large quantities during the asexual
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reproduction in any medium, provided the ortheir concentration represents a dynamic equilibrium
[4]. Orthologs are not found in other species of
human malaria [5]. Antibody detection of PFHRP2
(which also picks up PFHRP3) is, therefore, a sensitive
method for the rapid diagnosis of P. falciparum malaria
using whole blood [6], as well as an in vitro drug sensitiv-
ity readout that has found increasing use in recent years
[7]. PFHRP2 is also released into plasma, where its con-
centration reflects the extent of current and previous
cycle parasite sequestration, a process considered critical
to the pathology of severe malaria [8].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Selection of samples examined for possible
Pfhrp2 and Pfhrp3 deletion
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teins more than two decades ago [1,9], their physio-
logical role in the lifecycle of P. falciparum has been
subject to a number of lines of investigation, with the
focus of most attention on haem polymerization [10]. A
degree of redundancy exists with parasites lacking one
or both of these proteins still able to propagate in asex-
ual stage culture and complete the entire parasite life
cycle [11-13]. Nevertheless, classical falciparum genetic
crosses in which one parent had a deletion of Pfhrp3
demonstrated complete [14] or partial [15] bias towards
Pfhrp3 inheritance (although the cross-over interval was
not fine enough to attribute enhanced fitness specifically
to Pfhrp3 as opposed to nearby genes). Perhaps surpris-
ingly, Pfhrp2 did not show inheritance bias in the HB3 x
Dd2 cross [15]; low-level transcription in the HB3 parent
[16] could potentially explain this in part or in whole.
In contrast to these studies on cultured isolates, prior
to 2010 no field isolates had been reported which lacked
either Pfhrp2 or Pfhrp3. However, relatively recent evidence
of significant numbers of parasites with deletion of one or
both genes has emerged in the Peruvian Amazon [17,18],
generating concerns over the reliability of PFHRP2-based
rapid diagnostic tests (RDTs) in this region. There has been
little evidence that deletion of either gene occurs to a
significant degree in Africa. This may reflect both the
true rarity of the event (given the predicted deleterious
effect on fitness), along with the higher multiplicities of
infection found in high transmission settings. It is there-
fore concerning that isolates from Mali lacking Pfhrp2
have now been described [19].
Both Pfhrp2 and Pfhrp3 also exhibit extensive insertion-
deletion polymorphism, and the potential for this to reduce
the accuracy of RDTs has been examined at national [20]
and global scales [21,22]. However, whether sequence vari-
ation is an important confounder in the assessment of
plasma concentration, and hence disease severity, has not
been studied. This study examined the relationship be-
tween Pfhrp2 sequence and plasma PFHRP2 concentration
in samples derived from a large group of African children
treated for severe malaria in the AQUAMAT trial [23].Country Site Available samples Samples tested (%)
DRC Kinshasa 420 6 (1.43)
The Gambia Banjul 60 2 (3.33)
Kenya Kilifi 378 12 (3.17)
Mozambique Beira 659 19 (2.88)
Rwanda Kigali 170 10 (5.88)
Nyanza 111 5 (4.50)
Tanzania Korogwe 534 3 (0.56)
Teule 901 15 (1.66)
Uganda Mbarare 593 5 (0.84)
Total 3826 77 (1.98)Methods
A PCR-based approach was used to answer a number of
related questions. First, Pfhrp2 deletions were sought in
parasites from patients admitted with a diagnosis of se-
vere malaria but who had very low or undetectable
plasma PFHRP2 levels by ELISA. Deletions in Pfhrp3
were also checked since by cross-reacting with PFHRP2,
the less abundant PFHRP3 allows RDTs to retain some
sensitivity even when Pfhrp2 deletions are present. Fi-
nally, the relationship between Pfhrp2 exon 2 length and
repeat structure and plasma concentration was explored.Samples
Samples were obtained from children enrolled in the
AQUAMAT trial, a large multinational trial comparing
quinine and artesunate for the treatment of severe mal-
aria in African children undertaken between October
2005 and July 2010 and described in detail elsewhere
[23]. Children were included if they showed signs of
severe malaria (defined by clinical criteria) and had a
positive P. falciparum lactate dehydrogenase RDT.
Patients were excluded if treated parenterally for more
than 24 hours before admission. Patients were rando-
mized to treatment with either parenteral artesunate or
quinine. Baseline blood samples included a peripheral
blood slide. Slide reading was performed by microsco-
pists at the Mahidol-Oxford Tropical Medicine Research
Unit and parasitaemia/μl was calculated from thin film
(count/1,000 RBCx125.6xHct) or thick film (count/200
WBCx40). Dried whole blood spots were used for mo-
lecular studies. EDTA blood for plasma PFHRP2 meas-
urement was received from nine of the 11 AQUAMAT
research sites in seven countries (Table 1).
DNA samples from established P. falciparum lines
(K1, Dd2, 3d7) were provided by MR4 and used to con-
trol Pfhrp2 and Pfhrp3 PCR results. A number of sam-
ples from within Asia were also tested to validate
methodology, confirming the finding [22] that Pfhrp2
exon 2 sequences from African samples are longer than
those from Cambodia, as they have substantially more
type 7 repeats. To reduce the potential confounding ef-
fect of differing clinical characteristics in patients
recruited in different sites, the relationship between
Pfhrp2 sequence and plasma concentration was focused
on sample sets from Mozambique and Tanzania (Teule).
Appropriate ethical approvals were granted by the Ox-
ford Tropical Research Ethics Committee, the Ethics
Committee of the Faculty of Tropical Medicine, Mahidol
University and the individual study site countries’ ethical
review boards.
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Parasite DNA from dried blood spots was extracted via
the QIAmp DNA Mini kit using the standard protocol
and stored at −20°C until use. For both Pfhrp2 and Pfhrp3,
a semi-nested PCR approach was used involving identical
primers and conditions to those already described by
Baker et al. [21]. These primers anneal to the conserved
end regions of exon 2 of Pfhrp2 and Pfhrp3, with the
intervening sequence encompassing the variable histidine-
rich repeats of these genes. To confirm P. falciparum
infection in Pfhrp2-negative samples or those with very
weak bands, a fully nested PCR Plasmodium species de-
tection approach was employed using specific oligo-
nucleotide primers to amplify a segment of ssrRNA
using published primers and conditions [24]. For Pfhrp2
sequencing, amplified DNA products were purified
using the Favorgen Gel/PCR purification kit according
to the manufacturer’s instructions. DNA concentrations
were estimated by agarose gel electrophoresis and sam-
ples sent for sequencing (using the Pfhrp2 internal for-
ward primer [21]) at Macrogen, Seoul, South Korea.
Plasma PFHRP2 was measured in freeze-thawed
EDTA plasma samples according to standard techni-
ques [25]. In brief a commercial sandwich ELISA kit
(Celisa, Cellabs, Sydney, Australia) was used according
to the manufacturer’s instructions with minor modifi-
cations and blinded to patient outcomes [8]. Pooled
reference plasma was derived from 20 subjects with
parasitaemia >200,000/μl and used to construct standard
curves.Figure 1 PfHRP2 levels and parasitaemias for samples examined. A: s
AQUAMAT centres; B: samples sequenced from Mozambique and TanzaniaStatistics
Comparisons of Pfhrp2 exon 2 length and repeat num-
ber were undertaken by the Mann–Whitney test in
GraphPad Prism.
Results
Assessment of possible deletion of Pfhrp2 or Pfhrp3
Plasma PFHRP2 was measured in 3,826 of the 5,426
children with pLDH-RDT-confirmed falciparum malaria
included in the AQUAMAT trial. The 80 samples asso-
ciated with lowest plasma PFHRP2 levels yielded 77
blood spots which were analysed using a semi-
quantitative approach for possible deletions in Pfhrp2 or
Pfhrp3 (Table 1, Figure 1a). These samples had a median
parasitaemia of 9,043/μl (compared to 79,397/μl for the
whole dataset). PCR for Pfhrp2 revealed bands of the
anticipated size in 70 cases; in seven cases (median para-
sitaemia 3,040/μl) no band could be obtained despite
repeated attempts. In all these Pfhrp2-negative cases, the
sample also had negative or very weak bands for Pfhrp3
as well as species identification, indicating that DNA
content of the sample was at or below the threshold of
detection. In an analogous manner, PCR for Pfhrp3 was
found to be positive in 67 samples, and was only nega-
tive (ten cases) when the other two reactions were nega-
tive or produced very dilute products.
Sequence polymorphism in Pfhrp2
In order to explore the relationship between Pfhrp2 se-
quence and plasma concentration, the aim was to obtainamples subjected to PCR for Pfhrp2 and Pfhrp3 across all relevant
(Teule site).
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zambique associated with extreme values of plasma
PFHRP2 (40 high, 40 low) but with relatively high per-
ipheral parasitaemias (greater than 10,000/μl) and hence
likely to produce reliable material for sequencing
(Figure 1b). Twenty-six clean PCR products suitable for
sequencing had already been obtained from these two
sites in the first phase of testing samples with low
PFHRP2 levels. An additional 62 (22 low PFHRP2, 40
high) samples therefore underwent DNA extraction and
Pfhrp2 PCR; all gave bands with no evidence of Pfhrp2
deletion. After sequencing, clear and complete exon 2
sequences were available in 34 samples from Mozam-
bique and 32 from Tanzania. Across these 66 samples,
37 patients had low PFHRP2 levels (median
(range) = 10.9 ng/ml (undetectable – 46.1)) while 29 had
high PFHRP2 levels (18,017 ng/ml (11,289–56,818)).
As expected from the gel electrophoresis results, and
consistent with previous findings [20-22], PCR products
were highly variable in length, as well as the numbers and
types of repeat (Figure 2a). For Mozambique the median
Pfhrp2 exon 2 PCR product length was 741 bp (range
627–816) and for Tanzania 759 (range 651–876) (p= 0.12;
Table 2). Of the repeat types described by Baker et al.,
types 2 (AHHAHHAAD) and 7 (AHHAAD) were the
most prominent (Figure 2b), constituting more than half
of each sequence; these were also the only repeat types
observed in all samples. All the other repeats documented
were fewer in number (no more than six of any repeat in
any sample). There was no significant difference in the
number of type 2, type 7 or any other repeat between Mo-
zambique and Tanzania (Figure 2b, Table 2) and the two
datasets were pooled to explore the possible association
between Pfhrp2 polymorphism and plasma levels.
Sequence length, number of type 2 repeats and num-
ber of type 7 repeats did not correlate with PFHRP2Figure 2 Pfhrp2 exon 2 length and repeat numbers according to coun
of type 2 and 7 repeats in each sample.plasma concentration when expressed as a continuous
variable (Figure 3a). There was also no significant differ-
ence in these sequence properties between low and high
categories of PFHRP2 (Figure 3b).
Discussion
PFHRP2 is released into the circulating plasma [8,26-
28] where it persists for several days [29]. Because of
the exponential rise in parasitaemia that occurs during
the development of P. falciparum in the blood, in
whole blood a large portion of PFHRP2 is located
within asexual parasites [27], and whole-blood PFHRP2
concentrations correlate, therefore, with peripheral
blood parasitaemia. By contrast, plasma PFHRP2 pro-
vides a summative picture of previous cycles of growth
that reflects sequestered parasite biomass rather than
circulating biomass [8]. Plasma PFHRP2 measurement
can therefore potentially be applied in the management
of severely ill patients in high transmission settings who
may be ill because of malaria or alternatively have an-
other severe illness, with malaria parasitaemia an inci-
dental finding [30]. Post-mortem reveals that 25% of
patients thought to have died of severe malaria have
other serious pathology [31]. Confident differentiation
of severe malaria from other pathologies where the
prevalence of malaria parasitaemia is high is very diffi-
cult [30]; observation of malarial retinopathy improves
the accuracy of diagnosis for cerebral malaria [32], but
requires skill and training and is rarely achievable in
practice outside centres of excellence. Since plasma
PFHRP2 derives from sequestered parasites that are
critical to the pathology of severe malaria, it has poten-
tial to differentiate ‘true’ severe malaria from alternative
illnesses in parasitaemic patients, as well as provide an
independent marker of prognostic significance in severe
malaria [8]. Plasma PFHRP2 levels were found to betry. A: frequency of each exon size (bin width of 20 bp); B: numbers
Table 2 Pfhrp2 exon 2 length and repeat polymorphism data by country
Population Mozambique Tanzania (Teule) Combined P value
Total number 34 32 66
Length: median (range) 741 (627–816) 759 (651–876) 751.5 (627–876) 0.12
Haplotypes 34 32 66
Repeats
Type 2 12 (10–17) 12 (8–16) 12 (8–17) 0.70
Type 7 7 (3–10) 8 (2–11) 7 (2–11) 0.22
The types and numbers of repeats for each sequence were examined using the repeat structure described by Baker et al. [21].
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pared to uncomplicated malaria in Indonesia [33] and
Thailand [8] although studies in Kenya [34] and Papua
New Guinea [35] did not find a significant difference.
Explanations for these apparently discrepant findings
include different classifications of disease severity as
well as differences in the intensity of transmission. A
particular problem in these studies, and in other studies
of severe malaria is the classification of children with
severe anaemia and low parasitaemia as having “severe
malaria”, many of whom have chronic anaemia and in-
cidental parasitaemia. These patients do not have large
numbers of sequestered parasites and so do not have
high plasma PFHRP2 concentrations.
The antibodies present in PFHRP2 RDT kits detect
the repetitive histidine-rich repeats encoded by exon 2
of Pfhrp2 (and Pfhrp3) [2,36]. This is a strength of
PFHRP2-based diagnosis, since the antigen sequence
appears many times within the protein and one protein
can be bound by several antibody molecules potentially
leading to amplification of signal and high assay sensitiv-
ity. However, the nature of the antigen detected opti-
mally by each RDT clearly differs between kits [2,36].Figure 3 Relationship between Pfhrp2 exon 2 length and plasma leveThe possibility that this might impair the accuracy of
RDTs was reflected for a time by a concern that certain
patterns of repeat polymorphism (relating to numbers of
type 2 and type 7 repeats) were associated with lower
levels of detection, based on a semi-quantitative analysis
of kit sensitivity [21]. Subsequent work has not sup-
ported this possibility and the performance of a range of
RDTs now appears unlikely to be confounded by se-
quence polymorphisms [22].
This study aimed to address the concern that quantifi-
cation of plasma PFHRP2 might be confounded by se-
quence polymorphism in terms of type and number of
histidine-containing repeats in PFHRP2. Among para-
sites from Mozambique and Tanzania, a diverse pattern
of repeat types was observed consistent with previous
studies from a wide range of African countries [20-22].
Within this variation, there was no relationship between
the number of repeats observed, or overall sequence
length, and plasma PFHRP2 level, mirroring the semi-
quantitative findings from studies examining rapid diag-
nostic tests [22]. These findings do not support the idea
that sequence polymorphism has a substantial influence
on ELISA-based PFHRP2 quantitation in Africanl. A: individual samples; B: categorized by PFHRP2 level.
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data that in Southeast Asian adult plasma PFHRP2 cor-
relates well with severity of disease [8,33], provide sup-
port for further work aimed at developing measurement
of plasma PFHRP2 as an aid to the diagnosis and the
management of severely ill African children [25].
Previous reports of field isolates with deletion of one
or both of these genes examined samples originating in
areas with generally low multiplicity of infection (MOI)
[17,18], or focused on samples from individuals with no
or few symptoms of malaria and hence likely to have
lower MOI [19]. In this survey of around 80 selected
parasite samples from patients admitted with a diagnosis
of severe malaria but with very low PFHRP2 plasma
levels across a number of African countries, there was
no evidence for deletion of either Pfhrp2 or Pfhrp3.
Multiplicity of infection was not measured, although it is
likely that a significant proportion of these samples con-
tained single infections, since around 10% contained in-
sufficient DNA to produce a PCR product in two
independent reactions. It is also worth noting that the
median asexual parasitaemia in this subgroup was about
9,000 parasites per μl, a figure similar to that associated
with false-negative RDTs in the recently published study
from Mali. The findings therefore provide a degree of re-
assurance regarding the prevalence of Pfhrp2 and Pfhrp3
deletion across the sites examined.
Conclusion
PFHRP2 sequence variation in parasites causing severe
malaria in Africa does not confound the quantification of
PFHRP2 antigen in plasma. This is a key element in the de-
velopment of plasma PFHRP2 concentration measurement
as a method for assessing African children who may have
severe falciparum malaria. The evidence supports the con-
cept that sequestered parasite biomass is the major cause
of variation of PFHRP2 concentration in patient samples.
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